scispace - formally typeset
Search or ask a question
Author

Pierre Rofail

Bio: Pierre Rofail is an academic researcher from Albany College of Pharmacy and Health Sciences. The author has contributed to research in topics: Mental health & Mainstream. The author has an hindex of 1, co-authored 1 publications receiving 5 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: The authors conclude with commentary on the market for pegfilgrastim in light of the growing debate surrounding the optimal selection of patients, treatment costs and future alternatives for the use of these agents in chemotherapy.
Abstract: For oncology patients, febrile neutropenia (FN) can be a serious and costly toxicity of chemotherapy, often forcing a reduction in chemotherapy dose intensity and/or duration. Several therapeutic agents are used to reduce the occurrence of neutropenic episodes: granulocyte colony-stimulating factors (G-CSFs) and granulocyte-macrophage colony-stimulating factors. Appropriate administration of colony-stimulating factors reduces the risk of FN episodes and the costs associated with FN treatment. In the USA, the two most commonly used G-CSFs are filgrastim and the longer-acting pegfilgrastim. This pharmacoeconomic review of pegfilgrastim briefly considers some of the early research of G-CSFs, then focuses on the most recent comparative studies of pegfilgrastim against the backdrop of forthcoming US patent expiration for both products. The authors conclude with commentary on the market for pegfilgrastim in light of the growing debate surrounding the optimal selection of patients, treatment costs and future alternatives for the use of these agents in chemotherapy.

8 citations

Posted ContentDOI
18 Jan 2023-medRxiv
TL;DR: In this article , an examination of the acts of discriminiation and hate crimes against the Asian American community and how their mental health has been impacted is presented, including anxiety, depression, and psychological stress.
Abstract: This article is an examination of the acts of discriminiation and hate crimes against the Asian American community and how their mental health has been impacted. The historical examination of acts against the Asian American community stem from acts against the Asian American community during both the yellow peril and the Roosevelt Era. Alongside current day institutionalized policies that are propagated by the media, the resurrection of historical tropes further act to seclude Asian Americans from mainstream society. These acts of seclusion further drive mental health inequality in Asian American society that include, but are not limited to: anxiety, depression, and psychological stress. These mental health inequalities are further subdivided into different ethnic groups that worsen as data is collected from older generations. More recently, COVID-19 has brought forth an upsurge in hate crimes that has only worsened the ability of Asian American youth to fully develop a racial identity; the upsurge in hate crimes is also coupled with invalidation of interethnic differences and invalidation of their discriminatory experiences. The synthesis of current day research will aid in the understanding of the mental health inequality in the Asian American community and aid in further studies that can address these plights.

Cited by
More filters
Journal ArticleDOI
TL;DR: Risks of FN and FN-related complications were generally lower for prophylaxis with pegfilgrastim versus prophYLaxis with short-acting G-CSFs, according to a systematic review of real-world comparative effectiveness studies.
Abstract: IntroductionFebrile neutropenia (FN) is a serious side-effect of myelosuppressive chemotherapy. Several clinical trials and observational studies have evaluated the effects of prophylactic granuloc...

52 citations

Journal ArticleDOI
TL;DR: This work addresses therapeutic approaches based on the principles of synthetic immunology that either ameliorate disorders of the immune system by interfering with the immune response, or improve diverse pathogenic conditions by exploiting immune cell effector functions.

42 citations

Journal ArticleDOI
TL;DR: Pegfilgrastim has pharmacological advantages over daily G-CSFs that makes it easily administrable, thus reducing the chance of incorrect delivery, and the once-per-cycle administration might explain the findings derived from observational studies suggesting a possible superior efficacy of pegfil grastim overdaily G- CSFs.
Abstract: Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects.Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile neutropenia in patients with solid tumors.Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the inappropriate employment of G-CSFs in clinical practice can partially explain its burden. Pegfilgrastim has pharmacological advantages ...

17 citations

Journal ArticleDOI
TL;DR: Pegfilgrastim reduced the costs incurred for both drugs and hospitalization for AEs as well as FN, although the total medical cost during the chemotherapy increased.
Abstract: Background Febrile neutropenia (FN), a decrease in blood neutrophils accompanied by fever, is a major adverse event (AE) associated with cancer chemotherapy. We aimed to estimate the direct medical costs associated with FN management in breast cancer patients within a clinical trial with pegfilgrastim, a pegylated form of recombinant granulocyte colony-stimulating factor (G-CSF). Methods We obtained data from 346 Japanese breast cancer patients in a randomized, placebo-controlled clinical trial comparing FN incidence due to TC adjuvant chemotherapy (docetaxel 75 mg/m2, cyclophosphamide 600 mg/m2) between pegfilgrastim-treated and placebo groups. We estimated mean costs for chemotherapy drugs, drugs for all AEs and FN, and hospitalization for all AEs and FN. We also calculated mean costs associated with drugs and hospitalization for FN specifically for patients who developed FN in the placebo group. Results For the pegfilgrastim and placebo groups, the total cost during the first cycle of chemotherapy was ¥189 135 and ¥98 106. This difference is associated with prophylactic use of pegfilgrastim. Our analysis clarified in the placebo group that FN incidents of 119/173 (68.6%), the mean drug cost related to all AEs and hospitalization caused by the first cycle of chemotherapy were ¥14 411and ¥11 180, respectively. The cost of each for FN treatment was ¥16 429 for the placebo group. The mean treatment cost for patients who developed FN in placebo group, was ¥11 145 for drugs and ¥28 420 for drugs and hospitalization. Conclusions Pegfilgrastim reduced the costs incurred for both drugs and hospitalization for AEs as well as FN, although the total medical cost during the chemotherapy increased. Our study constitutes baseline data for further health economic evaluations of pegfilgrastim.

7 citations

Journal ArticleDOI
TL;DR: The functional benefits of EKP are demonstrated, by which the EKKP-GCSF fusion protein produced in Escherichia coli exhibits improved pharmacokinetics and prolonged bioactivity in vivo.

3 citations